Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | MMP1 | P03956 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | MMP12 | P39900 | 1/20 | 0.61 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | STAT1 | P42224 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28117924 | 0.92 | KMT2A (0.69) | KDM4EMAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL20119309 | 0.89 | TDP1 (0.69) | KDM4EMAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5335214 | 0.85 | MAPT (0.63) | KDM4EMAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL4425326 | 0.83 | KDM4E (0.59) | KDM4EMAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5049642 | 0.83 | HCAR2 (0.60) | KDM4EMAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL28707037 | 0.82 | HCAR2 (0.64) | KDM4EMAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1787511 | 0.82 | HCAR2 (0.64) | KDM4EMAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL312910 | 0.82 | TDP1 (0.81) | KDM4EMAPTCYP2C9CYP2C19MMP1 | |
| SCHEMBL1787512 | 0.81 | HCAR2 (0.67) | KDM4EMAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL27915090 | 0.80 | KDM4E (0.68) | KDM4EMAPTCYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE C | 2006-02-02 | — | — | US | claimed |
| EP-1362028-A2 | ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | claimed |
| US-20020156061-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2002-10-24 | — | — | US | claimed |
| WO-2002064547-A2 | ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| US-7214712-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-6995151-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE C | 2006-02-02 | — | — | US | disclosed |
| EP-1536786-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1531904-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1530475-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| EP-1530467-A2 | COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2004007024-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006931-A2 | PHARMACEUTICAL COMPOSTIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006912-A2 | COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006913-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1362028-A2 | ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20020156061-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002064547-A2 | ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | MMP13, MMP11, MMP3 | KDM4E 2468/4885MAPT 4637/4885CYP1A2 857/4885 |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | KDM4E 2484/4885MAPT 2826/4885CYP1A2 3013/4885 |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | KDM4E 476/4885MAPT 1345/4885CYP1A2 429/4885 |
| US-20020156061-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | MMP13, MMP1, MMP11 | KDM4E 2636/4885MAPT 4604/4885CYP1A2 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.